The broad, shortage-based compounding pathway ended after the FDA resolved the semaglutide and tirzepatide shortages, and in April 2026 the FDA proposed excluding these drugs from the 503B outsourcing-facility bulks list, with a comment period through June 29, 2026
The FDA also said that some compounding pharmacies claiming to sell semaglutide might instead be selling other formulations of the chemical, like semaglutide sodium and semaglutide acetate
General principles for restarting GLP-1 medications include: Adequate oral intake : You should be tolerating a normal diet (or your usual post-operative diet plan) without significant nausea or vomiting Resolution of post-operative ileus : Normal bowel function should have returned, particularly after abdominal or pelvic surgery Stable clinical condition : Any post-operative complications should be resolved, and you should be recovering as expected Medical team approval : Always confirm with your surgical team or GP before restarting If you've been off a GLP-1 medication for several weeks, your doctor may recommend re-titrating the dose (starting at a lower dose and gradually increasing) to minimise gastrointestinal side effects when restarting
Nausea stems from slower stomach emptying and GLP-1 receptor activation in nausea-control brain centers
Higher-quality providers disclose these breakdowns clearly
[Online] Ozempic Drug Interactions Checker (n.d.) Drugs.com